Canaccord Genuity restated their hold rating on shares of Illumina, Inc. (NASDAQ:ILMN) in a research note issued to investors on Wednesday. They currently have a $170.00 price target on the life sciences company’s stock.

A number of other analysts also recently issued reports on the company. BidaskClub downgraded Illumina from a sell rating to a strong sell rating in a research report on Tuesday, July 25th. Barclays PLC restated a hold rating and issued a $150.00 price target on shares of Illumina in a research report on Wednesday, July 19th. Morgan Stanley restated an underweight rating and issued a $122.00 price target (up from $115.00) on shares of Illumina in a research report on Monday, July 10th. Finally, Vetr upgraded Illumina from a buy rating to a strong-buy rating and set a $197.84 price target for the company in a research report on Monday, July 3rd. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of Hold and a consensus price target of $167.02.

Illumina (NASDAQ ILMN) opened at 174.92 on Wednesday. Illumina has a 12 month low of $119.37 and a 12 month high of $189.48. The stock has a market capitalization of $25.54 billion, a P/E ratio of 35.40 and a beta of 0.84. The firm’s 50-day moving average is $174.65 and its 200-day moving average is $171.62.

COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.watchlistnews.com/illumina-inc-ilmn-stock-rating-reaffirmed-by-canaccord-genuity/1462577.html.

In other Illumina news, insider Michel Bouchard sold 5,740 shares of Illumina stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $184.68, for a total value of $1,060,063.20. Following the transaction, the insider now owns 22,255 shares in the company, valued at $4,110,053.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Charles Dadswell sold 1,609 shares of Illumina stock in a transaction dated Wednesday, May 3rd. The shares were sold at an average price of $187.07, for a total value of $300,995.63. Following the completion of the transaction, the senior vice president now owns 10,936 shares in the company, valued at approximately $2,045,797.52. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 125,248 shares of company stock worth $22,281,673. Insiders own 1.60% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the stock. First Citizens Bank & Trust Co. raised its position in Illumina by 0.4% in the second quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock valued at $536,000 after buying an additional 12 shares during the period. Patten Group Inc. raised its position in Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock valued at $166,000 after buying an additional 25 shares during the period. Puzo Michael J raised its position in Illumina by 0.4% in the second quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock valued at $1,032,000 after buying an additional 25 shares during the period. Forte Capital LLC ADV raised its position in Illumina by 1.6% in the first quarter. Forte Capital LLC ADV now owns 2,185 shares of the life sciences company’s stock valued at $373,000 after buying an additional 35 shares during the period. Finally, Gemmer Asset Management LLC raised its position in Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock valued at $117,000 after buying an additional 37 shares during the period. Institutional investors own 93.75% of the company’s stock.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.